Literature DB >> 29304364

Systematic review of health-related quality of life and patient-reported outcome measures in gestational trophoblastic disease: a parallel synthesis approach.

Jane Ireson1, Georgina Jones2, Matthew C Winter3, Stephen C Radley4, Barry W Hancock3, John A Tidy3.   

Abstract

Gestational trophoblastic disease is a rare complication of pregnancy that can develop into cancer. Medical outcomes of gestational trophoblastic disease are well researched, but the effect of the disease on health-related quality of life (HRQOL) requires attention if care is to be improved. This systematic review was designed to establish the effect of gestational trophoblastic disease and its treatment on HRQOL and to identify the appropriateness of HRQOL measures. Quantitative studies found HRQOL in long-term survivors of gestational trophoblastic disease to be at or above population norms. The disease had a negative effect on HRQOL for patients who experienced physical, psychological, and social sequelae related to the condition. Clinically significant levels of anxiety, depression, sexual dysfunction, and fertility-related distress were found in these patients. The results should be treated with caution because the evidence base was limited to small heterogeneous samples, data were retrospective, and a range of measures was used. Within qualitative studies on HRQOL for survivors of gestational trophoblastic disease, new conditions emerged, including nerve damage, fatigue, amenorrhoea, and grief. These areas are not captured in existing patient-reported outcome measures, and the content might not be valid for this population. Further qualitative research might lead to the development of a specific patient-reported outcome measure for gestational trophoblastic disease, providing reliable, meaningful, and valid assessments, and allowing longitudinal data to be obtained.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29304364     DOI: 10.1016/S1470-2045(17)30686-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  5 in total

Review 1.  A review of quality of life (QOL) assessments and indicators: Towards a "QOL-Climate" assessment framework.

Authors:  Ronald C Estoque; Takuya Togawa; Makoto Ooba; Kei Gomi; Shogo Nakamura; Yasuaki Hijioka; Yasuko Kameyama
Journal:  Ambio       Date:  2018-09-11       Impact factor: 5.129

2.  Hepatic toxicity following actinomycin D chemotherapy in treatment of familial gestational trophoblastic neoplasia: A case report.

Authors:  Xiyan Mu; Rutie Yin; Danqing Wang; Liang Song; Yu Ma; Xia Zhao; Qingli Li
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

3.  Direct comparisons of efficacy and safety between actinomycin-D and methotrexate in women with low-risk gestational trophoblastic neoplasia: a meta-analysis of randomized and high-quality non-randomized studies.

Authors:  Jiatao Hao; Weihua Zhou; Mengzhao Zhang; Hui Yu; Taohong Zhang; Ruifang An; Yan Xue
Journal:  BMC Cancer       Date:  2021-10-18       Impact factor: 4.430

4.  Association between gestational trophoblastic disease (GTD) history and clinical outcomes in in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles.

Authors:  Xinyu Cai; Mei Zhang; Chenyang Huang; Yue Jiang; Jidong Zhou; Manlin Xu; Guijun Yan; Haixiang Sun; Na Kong
Journal:  Reprod Biol Endocrinol       Date:  2022-02-04       Impact factor: 5.211

5.  The psychological impact of gestational trophoblastic disease: a prospective observational multicentre cohort study.

Authors:  L J Blok; M M Frijstein; Y K Eysbouts; Jae Custers; Fcgj Sweep; Car Lok; P B Ottevanger
Journal:  BJOG       Date:  2021-08-10       Impact factor: 7.331

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.